[Effect of recombinant human thrombin for hemostasis in liver resection: a randomized controlled phase â ¢ clinical trial].

Objective: To evaluate the hemostatic efficacy, safety and immunogenicity of recombinant human thrombin in the treatment of liver wounds that still ooze after conventional surgical hemostasis. Methods: A multicenter, stratified randomized, double-blind, placebo-controlled phase Ⅲ trial with a planned enrollment of 510 subjects at 33 centers, with a 2∶1 randomization to the thrombin group versus the placebo group. An interim analysis will be conducted after approximately 70% of the subjects have completed the observation period. The primary efficacy endpoint was the rate of hemostasis within 6 minutes at the point of bleeding that could be evaluated. Safety analysis was performed one month after surgery, and the positive rates of anti-drug antibody (ADA) and neutralizing antibody were evaluated. Results: At the interim analysis, a total of 348 subjects had been randomized and received the study drug (215 were male and 133 were female). They were aged 19-69 (52.9±10.9)years. Among them, 232 were in the thrombin group and 116 were in the placebo group, with balanced and comparable demographics and baseline characteristics between the two groups. The hemostasis rate at 6 minutes was 71.6% (95%CI:65.75%-77.36%) in the thrombin group and 44.0% (95%CI: 34.93%-53.00%) in the placebo group, respectively (P<0.001). No grade≥3 drug-related adverse events and no drug-related deaths were reported from the study.No recombinant human thrombin-induced immunologically-enhanced ADA or immunologically-induced ADA was detected after topical use in subjects. Conclusion: Recombinant human thrombin has shown significant hemostatic efficacy and good safety in controlling bleeding during liver resection surgery, while also demonstrating low immunogenicity characteristics.

The role of miR-99b in mediating hepatocellular carcinoma invasion and migration.

Since this article has been suspected of research misconduct and the corresponding authors did not respond to our request to prove originality of data and figures, "The role of miR-99b in mediating hepatocellular carcinoma invasion and migration, by C.-J. Liu, J.-H. Yang, F.-Z. Huang, J.-H. Yang, C.-P. Liu, X.-H. Mao, W.-M. Yi, X.-B. Shen, C. Peng, M.-F. Chen, B. Jiang, J.-S. Wu, published in Eur Rev Med Pharmacol Sci 2018; 22 (8): 2273-2281-DOI: 10.26355/eurrev_201804_14815-PMID: 29762829" has been withdrawn. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/14815.

The role of miR-99b in mediating hepatocellular carcinoma invasion and migration.

OBJECTIVE: Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer in adults with a high rate of malignancy. The potent invasion and migration of HCC mainly impact the prognosis and recurrence of the disease. Our previous study found that miR-99b was highly expressed in HCC, and its expression was associated with vascular invasion. It was speculated that miR-99b may play a role in HCC invasion and migration, while the specific mechanism remains unclear. MATERIALS AND METHODS: qRT-PCR was applied to detect expressions of miR-99b and KAI1 genes in L02, HepG2, and MHCC97H cells. HepG2 cells were transfected with miR-99b inhibitor, miR-99b mimic, and NC. Flow cytometry was used to test cell cycle and apoptosis. Dual-luciferase reporter gene assay was adopted to validate the target gene of miR-99b. Wound healing assay was used to detect cell migration. Transwell assay was performed to detect cell invasion. Western blot was performed to detect KAI1, E-cadherin, and N-cadherin expressions. Immunofluorescence assay was adopted to test Vimentin expression. RESULTS: The level of miR-99b was reduced in L02 while up-regulated in MHCC97H. By contrast, the expression of KAI1 was increased in L02 but declined in MHCC97H. The transfection of miR-99b mimic inhibited HepG2 apoptosis and accelerated cell cycle. MiR-99b suppressed KAI gene expression through targeting its 3'-UTR. MiR-99b mimic or si-KAI1 transfection promoted cell invasion and migration, while their simultaneous action significantly enhanced cell invasion and migration. The overexpression of miR-99b or knockdown of KAI1 significantly weakened HepG2 cell adhesion, reduced E-cadherin expression, upregulated N-cadherin and Vimentin, and promoted cell epithelial-mesenchymal transition (EMT). CONCLUSIONS: MiR-99b contributes to promoting function in HCC migration and invasion through inhibiting KAI1 expression.

Corneal flap thickness in laser in situ keratomileusis using an SCMD manual microkeratome.

PURPOSE: To evaluate corneal flap thickness in laser in situ keratomileusis (LASIK) and to measure variables correlated with corneal flap thickness. SETTING: Kangnam St. Mary's Hospital, Department of Ophthalmology, College of Medicine, The Catholic University of Korea, Seoul, Korea. METHODS: This prospective study comprised 69 eyes of 66 patients having LASIK with the VISX Star laser and SCMD manual microkeratome. Corneal thickness, keratometry, and refractive error were measured preoperatively, the time taken to complete the corneal flap and its thickness were recorded intraoperatively, and visual outcome was followed postoperatively. Corneal flap thickness was calculated as the thickness of the corneal stromal bed subtracted from the total corneal thickness. RESULTS: Mean corneal flap thickness was 137.18 microns +/- 33.66 (SD). The thickness in 32 eyes (46.4%) was less than 135 microns, in 17 eyes (24.6%) from 135 to 165 microns, and in 20 eyes (29.0%) greater than 165 microns. There was no relationship between corneal flap thickness and degree of myopia, steepening of cornea, or time taken to complete the flap. However, the thickness of the corneal flap increased with the thickness of the cornea. Visual outcome was slightly better in the group with thick corneal flaps than in the one with thin corneal flaps, although the difference was not statistically significant. CONCLUSION: Corneal flap thickness was variable in LASIK using the SCMD microkeratome. There was a correlation between corneal flap thickness and preoperative corneal thickness.

A randomized comparative study of the performance of seven different sizes of the Mahua Ring inserted following measurement of the uterine cavity and one size of the same ring.

A comparative study of the performance of multi-sizes of the Mahua Ring inserted following measurement of the uterine cavity and one size of the same ring assigned at random was carried out from November 1984 to September 1985 at two hospitals in Tianjin. The experiences of 800 acceptors were analysed by life-table techniques. At the end of two years, net cumulative first segment continuation rates of the multi-size and one-size Mahua device were 88.0 and 88.2, respectively. The results revealed that there was no significant difference between the groups. It is suggested that to insert one size of the Mahua Ring is as effective as the insertion of many sizes of the Mahua Ring.